"Revlimid" A Step Closer To Being Approved For New Cases Of Multiple Myeloma
7/12/2013
Celgene Corp's cancer drug Revlimid (lenalidomide) met its main goal in the drug's phase III late-stage trial, meaning that the medication is one step closer to being approved for new cases of multiple myeloma. Multiple myeloma is also known as plasma cell myeloma. It is a form of cancer that affects the plasma cells - white blood cells found in the bone marrow...
Skin Cancer: One Tumor Surprisingly More Deadly Than Multiple Melanomas
7/12/2013
In a study published online by the Journal of the American Medical Association (JAMA), Dr. Berwick and her team from the University of New Mexico Cancer Center discovered that patients with multiple melanoma tumors have a better chance of survival than those with only one...
Study Of Dogs With Microchimerism Should Improve Understanding Of Disease In Humans
7/12/2013
Some people possess a small number of cells in their bodies that are not genetically their own; this condition is known as microchimerism. It is difficult to determine potential health effects from this condition because of humans' relatively long life-spans. Now, researchers at the University of Missouri have found that microchimerism can be found in dogs as well...
More Direct Control Offered By Robotic Ultrasound During Kidney Cancer Surgery
7/12/2013
While the use of ultrasound to identify tumors during kidney cancer surgery is gaining acceptance, a research team at Henry Ford Hospital has successfully taken it a step further by showing an added benefit when the procedure is done robotically...
Research Team Stumbles Upon Potential Blood Test for Heart Disease
7/12/2013
Every 40 seconds, someone in the US dies of cardiovascular disease (CVD). It is the number one cause of death in the world, but researchers from the University of Nebraska Medical Center (UNMC) may have stumbled upon an easy way to predict - and maybe prevent - deaths from this common disease. Dr...
Too Frequent Cervical-Cancer Screenings May Cause More Harm Than Good
7/11/2013
For decades, women between the ages of 21 and 69 were advised to get annual screening exams for cervical cancer. In 2009, however, accumulating scientific evidence led major guideline groups to agree on a new recommendation that women be screened less frequently: every three years rather than annually...
Omega 3 fish oils linked to prostate cancer risk
7/11/2013
Eating a lot of oily fish or consuming omega supplements may not be good for a man's health. New research reveals that males with high blood concentrations of omega-3 fatty acids are at a higher risk of developing prostate cancer. The finding comes from a large prospective study published in the Journal of the National Cancer Institute...
Omega 3 Fish Oils Linked To Increased Prostate Cancer Risk
7/11/2013
Eating a lot of oily fish or consuming omega supplements may not be good for a man's health. New research reveals that males with high blood concentrations of omega-3 fatty acids are at a higher risk of developing prostate cancer. The finding comes from a large prospective study published in the Journal of the National Cancer Institute...
EMA Lifts Conditional Status For GSK's Votrient® (Pazopanib) And Grants Full Approval
7/11/2013
GlaxoSmithKline (GSK) has announced that the European Medicines Agency (EMA) has agreed to remove the conditional status of the marketing authorisation for Votrient (pazopanib) and convert it to a full marketing authorisation. Pazopanib was granted a conditional licence in the European Union in June 2010...
Patrys Limited (ASX: PAB), a clinical stage biotechnology company, announced today that scientific collaborators at Macquarie University (Macquarie), Sydney, have been awarded a $427,510 Australian Government grant to support the development of new highly sensitive, non-invasive cancer diagnostic kits using Patrys' lead candidate PAT-SM6...